Glepaglutide for Short Bowel Syndrome

(EASE SBS 5 Trial)

This trial explores a treatment called glepaglutide for individuals with Short Bowel Syndrome (SBS), a condition where part of the intestine is missing or not functioning properly. The main goal is to determine if glepaglutide is effective and safe for those who rely on parenteral support (nutrition or hydration given through a vein) at least three times a week. Participants will receive either glepaglutide or a placebo to compare results. Those who have had SBS for a while, require regular parenteral support, and have no planned surgeries might find this trial suitable. As a Phase 3 trial, this study represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that glepaglutide, a treatment for short bowel syndrome, is safe and well-tolerated. Participants in previous studies experienced significant improvements in their condition, with only minor side effects. Some studies highlighted that glepaglutide reduced the need for intravenous nutrition without causing serious problems. This suggests that patients generally receive the treatment well, with safety data supporting its use in clinical trials.¹²³⁴⁵

Glepaglutide is unique for treating Short Bowel Syndrome because it mimics a natural hormone in the body called glucagon-like peptide-2 (GLP-2). This hormone plays a crucial role in helping the intestines absorb nutrients more effectively. Unlike current treatments, which often involve complex surgeries or nutrient infusions, glepaglutide offers a simpler, peptide-based approach that directly enhances intestinal function. Researchers are excited because this mechanism could lead to improved nutrient absorption and overall quality of life for patients without the need for invasive procedures.

Studies have shown that glepaglutide effectively treats short bowel syndrome (SBS). Patients with SBS who received glepaglutide absorbed more nutrients and fluids, reducing their need for parenteral support. One study found that 65.7% of patients taking glepaglutide experienced a significant positive response. Participants in this trial will receive either glepaglutide or a placebo. These findings suggest that glepaglutide can help people with SBS rely less on external nutritional support, enhancing their quality of life.¹²³⁶⁷